ASPE Reports Health Care Workforce Shortages Will Worsen By 2030

The health care workforce, which was already experiencing under-staffing prior to the pandemic, fluctuated wildly in the last two years, and shortages of providers are expected to deepen dramatically by 2030, according to a new report from the HHS Assistant Secretary for Planning and Evaluation released Wednesday (May 4). In the initial stages of the pandemic, shortages were caused by rampant furloughs. High turnover rates, burnout and disproportionate costs from travel nurses exacerbated the gaps, ASPE says. Shortages are expected...
Article Type: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 05/12/2022
CMS Volume: 
Vol. 25, No. 19
HEA Issue: 
Health Exchange Alert Weekly Report - 05/11/2022
HEA Volume: 
Vol. 10, No. 19
Author: 

WH Reviewing Two FDA Genomic Alterations Guidances

The White House is reviewing two FDA guidances that are expected to lay out how the agency will regulate genomic alterations of animals and that one source suspects will describe how the agency will exercise regulatory flexibility for intentional genomic alterations. FDA sent the guidances -- one draft and one final -- to the White House budget office on April 27, two months after making its first low-risk determination for animals that have undergone a genomic alteration. The first document...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 05/06/2022
FDA Volume: 
Vol. 28, No. 18
Author: 

Bancel Says It’s Too Late To Adopt Redesigned COVID-19 Vaccine For Fall

It’s unlikely that companies would be able to produce modified COVID-19 vaccines in sufficient quantities by August if FDA decides in June that the current composition of vaccines should be changed ahead of the fall season, Moderna CEO Stéphane Bancel said Wednesday (May 4). “I don't think any manufacturer will be able to be ready in August to fill that channel with product because that only leaves you with July to basically make products in the tens of millions of...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 05/09/2022
IDP Volume: 
Vol. 5, No. 19
Author: 


Lobbyists Hope To Keep Abortion Out Of Telehealth Lobbying

Telehealth stakeholders hope to keep the new firestorm over abortion away from telehealth discussions out of fear that virtual health services will be sucked into a partisan debate as they lobby for bipartisan legislation to extend COVID-19 pandemic telehealth flexibilities. But women’s reproductive rights groups stress that telehealth can play a key role in access to medication abortion as almost half of U.S. states have either ramped up abortion restrictions or are taking steps to do so as the Supreme...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 

Alaska Considering Bill On Telehealth Flexibility, Payment Parity

A bill advancing through the Alaska Legislature would permanently extend telehealth flexibilities in the state past the end of the federal public health emergency and establish payment parity for services provided digitally. The legislation, House Bill 265, if enacted would permanently allow all health care providers licensed in Alaska to treat patients via telehealth without a requirement for an initial in-person visit, reduce barriers to prescribing controlled substance medications via telehealth, expand Medicaid coverage for telemedicine and ensure payment parity...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 

User Fee Bill Requires Sponsors To Submit Trial Diversity Plans To FDA

House lawmakers’ draft user fee legislation includes several measures aimed at increasing diversity in clinical trials, including a requirement that drug and device sponsors provide FDA with diversity action plans that lay out their trial enrollment goals and explain how they plan to meet those goals. The legislation also calls for FDA to issue draft guidance on trial diversity plans and decentralized clinical trials, provide a public report summarizing the diversity action plans, and hold a public meeting on trial...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 05/06/2022
FDA Volume: 
Vol. 28, No. 18
Author: 

Antibiotic Incentives, LDT Reform Left Out Of E&C’s Draft User Fee Bill

The House Energy & Commerce Committee on Wednesday (May 4) unveiled a draft user fee reauthorization package that addresses several hot-button issues, including FDA’s accelerated approval pathway and inspection authorities , but missing from the legislation are measures to incentivize antimicrobial drug development and give FDA authority over laboratory-developed tests. Key lawmakers have introduced antimicrobial drug and LDT legislation and have indicated they would like to get them passed with a larger legislative vehicle. Both issues have been a key...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 05/06/2022
FDA Volume: 
Vol. 28, No. 18
Author: 




Pages

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.